1229006-35-2

Upstream product

• 1229006-34-1 C₁₈H₁₈N₂O₄ 
• 61049-69-2 3-O-benzylmaltol 
• 100-39-0 benzyl bromide 
• 1229006-33-0 C₁₇H₁₉NO₆ 
• 1229006-32-9 C₁₇H₁₇NO₄ 
• 1229006-31-8 C₁₆H₁₅NO₄ 
• 500371-01-7 3-(benzyloxy)-4-oxo-4H-pyran-2-carbaldehyde 
• 119736-16-2 3-(benzyloxy)-1-((tert-butoxycarbonyl)amino)-4-oxo-1,4-dihydropyridine-2-carboxylic acid ethyl ester 
• 1229006-11-4 C₂₀H₁₆O₃ 
• 1206102-04-6 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one 

Downstream Products

• 1229006-36-3 7-(benzyloxy)-N-(4-fluorobenzyl)-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]-oxazine-9-carboxamide 

Relevant academic research and scientific papers

Intermediate of these pyridonecarboxylic carbamoylalkanoic and HIV integrase inhibitor

A synthesis approach providing an early ring attachment via a bromination to compound I-I yielding compound II-II: whereby a final product such as AA: can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.

PROCESSES AND INTERMEDIATES FOR CARBAMOYLPYRIDONE HIV INTEGRASE INHIBITORS

Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a comopound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P 1 P3, R3 and Rx are as described herein.